Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have earned a consensus rating of “Buy” from the twenty-one ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $145.71.
ALNY has been the subject of a number of research analyst reports. Piper Sandler cut their target price on shares of Alnylam Pharmaceuticals from $147.00 to $142.00 in a research report on Tuesday, April 14th. Evercore ISI assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Friday, April 24th. They issued a “buy” rating and a $160.00 target price for the company. ValuEngine raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. UBS Group boosted their price objective on shares of Alnylam Pharmaceuticals from $111.00 to $122.00 and gave the company a “neutral” rating in a research report on Thursday, May 28th. Finally, BidaskClub raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, June 20th.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 34,765 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $143.22, for a total value of $4,979,043.30. Following the sale, the chief executive officer now owns 232,354 shares in the company, valued at approximately $33,277,739.88. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Barry E. Greene sold 22,265 shares of the business’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $149.99, for a total transaction of $3,339,527.35. Following the completion of the sale, the president now owns 84,501 shares in the company, valued at approximately $12,674,304.99. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 96,812 shares of company stock worth $13,878,051. 3.50% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in ALNY. Oppenheimer Asset Management Inc. purchased a new stake in Alnylam Pharmaceuticals in the 1st quarter worth $28,000. Sowell Financial Services LLC lifted its stake in Alnylam Pharmaceuticals by 1,992.0% in the 4th quarter. Sowell Financial Services LLC now owns 523 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 498 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in Alnylam Pharmaceuticals by 84.1% in the 1st quarter. Exchange Traded Concepts LLC now owns 707 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 323 shares in the last quarter. Advisor Group Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals in the 1st quarter worth $159,000. Finally, Tower Research Capital LLC TRC purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth $181,000. Institutional investors and hedge funds own 93.42% of the company’s stock.
NASDAQ:ALNY traded down $3.99 during trading hours on Tuesday, reaching $147.91. The company had a trading volume of 499,100 shares, compared to its average volume of 828,757. The company has a current ratio of 4.68, a quick ratio of 4.48 and a debt-to-equity ratio of 0.20. Alnylam Pharmaceuticals has a 52 week low of $69.11 and a 52 week high of $158.37. The firm has a market cap of $17.06 billion, a price-to-earnings ratio of -18.42 and a beta of 1.87. The firm’s 50 day moving average price is $138.97 and its 200-day moving average price is $124.28.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.62) EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $0.27. Alnylam Pharmaceuticals had a negative net margin of 310.01% and a negative return on equity of 57.63%. The business had revenue of $71.94 million during the quarter, compared to the consensus estimate of $90.45 million. During the same quarter in the previous year, the firm posted ($1.42) EPS. The firm’s revenue was up 173.6% on a year-over-year basis. On average, analysts forecast that Alnylam Pharmaceuticals will post -6.17 earnings per share for the current fiscal year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Featured Story: FAANG Stocks
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.